<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04763642</url>
  </required_header>
  <id_info>
    <org_study_id>20210202ORCH</org_study_id>
    <nct_id>NCT04763642</nct_id>
  </id_info>
  <brief_title>The Comparison of Miniinvasive and Open Pancreaticoduodenectomy for Cancer Pancreaticobiliary Zone</brief_title>
  <official_title>The Comparison of Miniinvasive and Open Pancreaticoduodenectomy for Cancer Pancreaticobiliary Zone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>State Budget Public Health Institution Scientific Research Institute - Ochapovsky Regional Clinical Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>State Budget Public Health Institution Scientific Research Institute - Ochapovsky Regional Clinical Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Comparison of Miniinvasive and Open Pancreaticoduodenectomy for Cancer Pancreaticobiliary&#xD;
      Zone&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Minimally invasive surgery is undoubtedly the method of choice for multiple gastrointestinal&#xD;
      surgical procedures because of its minimally invasive nature and number of benefits such as&#xD;
      reducing postoperative pain, shorter hospital stays, and earlier return to work. Current&#xD;
      advances in technological innovation and surgical strategies have made surgical procedures on&#xD;
      the pancreas a routine practice. However, the use of new surgical techniques in pancreatic&#xD;
      surgery has been slow due to the complexity of the operations and the steep learning curve&#xD;
      required for their use. For example, minimally invasive pancreatoduodenectomies (MIPD) have&#xD;
      not yet become widespread. Due to these interventions have a complex reconstructive stage&#xD;
      MIPD are still performed in a very few centers by specialized surgeons.&#xD;
&#xD;
      Although laparoscopic PD was first described in 1994 and the robotic approach in 2003, MIPD&#xD;
      still account for less than 14% of all DPE cases. The multicenter randomized controlled trial&#xD;
      (LEOPARD-2) for the first time compared laparoscopic and open pancreatoduodenectomy for&#xD;
      pancreatic or periampullary tumors. The study that involved 99 patients did not reveal the&#xD;
      superiority of laparoscopic PD (LPD) and provided an estimated mortality of 6%; 5 patients&#xD;
      died in the laparoscopy group and 1 patient died in the group open PD. The trial was stopped&#xD;
      early due to high mortality in the migratory invasive interventions group. Therefore,&#xD;
      advantages of minimally invasive procedures for removal of pancreato-biliary zone tumors&#xD;
      remain controversial.&#xD;
&#xD;
      In our study, we analyzed perioperative surgical outcomes and short-term survival outcomes in&#xD;
      patients undergoing MIPD, including LPD and robotic PD (RPD), as well as &quot;open&quot; proximal&#xD;
      pancreatoduodenectomy (OPD).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">January 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall complications</measure>
    <time_frame>up to 30 days</time_frame>
    <description>The proportion of all complications after operation accounted for the total number of patients</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pancreatic fistula</measure>
    <time_frame>up to 30 days</time_frame>
    <description>The international study group (ISGPF) definition: A drain output of any measurable volume of fluid on or after postoperative day 3 with an amylase content greater than 3 times the serum amylase activity. Three different grades of postoperative fistula (grades A, B, C) are defined according to the clinical impact on the patient's hospital course.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intra-abdominal bleeding</measure>
    <time_frame>up to 30 days</time_frame>
    <description>he International Study Group of Pancreatic Surgery (ISGPS) definition: Blood loss through abdominal drains or nasogastric tube;hematemesis or melena; clinical deterioration of the patient; unexplained hypotension or tachycardia; or laboratory findings such as a decreasing hemoglobin concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intra-abdominal infection</measure>
    <time_frame>up to 30 days</time_frame>
    <description>Positive cultures of collection of fluid or blood,or persistent fever necessitating treatment with antibiotics and positive detection in image test.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay (day)</measure>
    <time_frame>Up to postoperative 2 months</time_frame>
    <description>Participants will be followed for the duration of hospital stay, an expected average of 2 weeks</description>
  </secondary_outcome>
  <other_outcome>
    <measure>progression-free survival</measure>
    <time_frame>Up to postoperative 3 years</time_frame>
    <description>The period between the beginning of treatment and the observation of disease progression or the occurrence of death for any reason</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Pancreatic Cancer</condition>
  <condition>Bile Duct Cancer</condition>
  <condition>Ampulla of Vater Cancer</condition>
  <arm_group>
    <arm_group_label>Laparoscopic Pancreaticoduodenectomy (LPD)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Robotic Pancreaticoduodenectomy (RPD)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Open Pancreaticoduodenectomy (OPD)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>pancreaticoduodenectomy</intervention_name>
    <description>Robotic Whipple operation Open Whipple operation Laparoscopic Whipple operation</description>
    <arm_group_label>Laparoscopic Pancreaticoduodenectomy (LPD)</arm_group_label>
    <arm_group_label>Open Pancreaticoduodenectomy (OPD)</arm_group_label>
    <arm_group_label>Robotic Pancreaticoduodenectomy (RPD)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age: 21-75 years&#xD;
&#xD;
          -  Clinically/histologically established diagnosis of the cancer;&#xD;
&#xD;
          -  Preoperative imaging assessment is resectable or borderline resectable&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Benign tumors of the head of pancreas;&#xD;
&#xD;
          -  Distant metastasis;&#xD;
&#xD;
          -  Conversion to laparotomy;&#xD;
&#xD;
          -  Instrumental findings of the tumor process prevalence;&#xD;
&#xD;
          -  General somatic status on the ASA III-V scale;&#xD;
&#xD;
          -  Acute pancreatitis;&#xD;
&#xD;
          -  Hyperbilirubinemia above 60 μmol/L (3.51 mg/dl) ((normal range, 4-20 μmol/L)).&#xD;
&#xD;
          -  Patients with intraoperative positive express-histological presence of tumor growth&#xD;
             along the border of the pancreas resection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Aleksandr N. Petrovsky, MD</last_name>
    <phone>+79094648456</phone>
    <email>a_petrovsky@mail.ru</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ochapovsky Regional Clinical Hospital № 1</name>
      <address>
        <city>Krasnodar</city>
        <state>Krasnodar Region</state>
        <zip>350068</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aleksandr N. Petrovsky, MD</last_name>
      <phone>+79094648456</phone>
      <email>a_petrovsky@mail.ru</email>
    </contact>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 13, 2021</study_first_submitted>
  <study_first_submitted_qc>February 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2021</study_first_posted>
  <last_update_submitted>February 18, 2021</last_update_submitted>
  <last_update_submitted_qc>February 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pancreatoduodenectomy</keyword>
  <keyword>miniinvasive</keyword>
  <keyword>complication</keyword>
  <keyword>Morbidity</keyword>
  <keyword>Mortality</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bile Duct Neoplasms</mesh_term>
    <mesh_term>Cholangiocarcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

